Abstract
Multidrug-resistant Pseudomonas aeruginosa is of increasing concern in pediatric patients. Ceftolozane/tazobactam is a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Pseudomonas; however, no data exist on its use in children. This report summarizes the treatment of a multidrug-resistant P. aeruginosa bloodstream infection in a pediatric leukemia patient with ceftolozane/tazobactam and provides the first description of its pharmacokinetics in pediatrics.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use*
-
Bacteremia / complications
-
Bacteremia / drug therapy*
-
Cephalosporins / therapeutic use*
-
Child
-
Drug Resistance, Multiple, Bacterial
-
Hospitalization
-
Humans
-
Leukemia / complications*
-
Male
-
Penicillanic Acid / analogs & derivatives*
-
Penicillanic Acid / therapeutic use
-
Pseudomonas Infections / complications
-
Pseudomonas Infections / drug therapy*
-
Pseudomonas aeruginosa
-
Tazobactam
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
ceftolozane
-
Penicillanic Acid
-
Tazobactam